Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07332221 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial

Name: Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial — clinical trial record (NCT07332221)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorHenan Cancer Hospital

Started2026-01-20

View on ClinicalTrials.gov ↗

Henan Cancer Hospital

107 trials monitored

See 2 trials at risk

Esophageal Cancer

1,010 trials monitored

See 51 trials at risk

This study is a prospective, multicenter, multi-cohort Phase III clinical trial. It primarily enrolls high-risk recurrent esophageal cancer patients who have undergone R0 resection after neoadjuvant chemoimmunotherapy. Eligible patients are stratified based on pathological lymph node status and receive either toripalimab monotherapy as maintenance treatment or clinical observation only.

Trial Details

NCT Number	NCT07332221
Lead Sponsor	Henan Cancer Hospital
Conditions	Esophageal Cancer
Enrollment	435 participants
Start Date	2026-01-20
Primary Completion	2029-10-01 (estimated)
Study Completion	2031-10-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-12